Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
While broad efforts toward getting an overview of immune cell and soluble factor alterations in COVID-19 are under way, a deep and comprehensive understanding of the mononuclear phagocyte system, including circulating progenitors, is still largely lacking. This study provides a reference for the mononuclear phagocyte response to SARS-CoV-2 infection and unravels mononuclear phagocyte dysregulations associated with severe COVID-19.
Article activity feed
-
SciScore for 10.1101/2020.08.25.20181404: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Briefly, 50 μl EDTA blood and 20 μl of antibody mix (6-color TBNK Reagent and CD123 BUV395 from BD, CD15 PB, CD193 BV605 and HLA-DR BV785 from Biolegend and CD14 PE-Cy5 from eBioscience) were added in BD trucount tubes and incubated for 15 min at room temperature in the dark. CD123suggested: (BioLegend Cat# 306032, RRID:AB_2566448)CD193suggested: (BD Biosciences Cat# 564188, RRID:AB_2738655)HLA-DR BV785suggested: (BioLegend Cat# 307641, RRID:AB_2561360)CD14suggested: None… SciScore for 10.1101/2020.08.25.20181404: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Briefly, 50 μl EDTA blood and 20 μl of antibody mix (6-color TBNK Reagent and CD123 BUV395 from BD, CD15 PB, CD193 BV605 and HLA-DR BV785 from Biolegend and CD14 PE-Cy5 from eBioscience) were added in BD trucount tubes and incubated for 15 min at room temperature in the dark. CD123suggested: (BioLegend Cat# 306032, RRID:AB_2566448)CD193suggested: (BD Biosciences Cat# 564188, RRID:AB_2738655)HLA-DR BV785suggested: (BioLegend Cat# 307641, RRID:AB_2561360)CD14suggested: NoneSoftware and Algorithms Sentences Resources Flow cytometry analysis: Acquired data was analyzed using DIVA (BD Biosciences), FlowJo v.10.5.3 (BD Biosciences) and Prism v. FlowJosuggested: (FlowJo, RRID:SCR_008520)8.0.2 (GraphPad Software Inc.) GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Algorithms used for dimensionality reduction were UMAP (Becht et al., Nature Biotechnology, 2018; https://github.com/lmcinnes/umap) and Phenograph (Levine et al., Cell, 2015; Phenographsuggested: (Phenograph, RRID:SCR_016919)Single cell analysis: Seurat version 3 was used to re-analyze single cell data. Seuratsuggested: (SEURAT, RRID:SCR_007322)In brief, scRNA-seq from previously published report22 was used and 10X Genomics filtered_feature_bc_matrix files were acquired from Gene Expression Omnibus (GEO; accession number GSE145926). Gene Expression Omnibussuggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)Ingenuity Pathway Analysis (IPA) was performed to study pathways (Content version: 51963813; Release Date: 2020-03-11; Ingenuity Systems) Ingenuity Pathway Analysissuggested: (Ingenuity Pathway Analysis, RRID:SCR_008653)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-